10.03.2014 11:46:01
|
Alexion Pharma Boosts 2014 Targets - Quick Facts
(RTTNews) - Alexion Pharmaceuticals, Inc. (ALXN) reported increasing its 2014 guidance for net product sales and non-GAAP earnings per share, to reflect its current expectation for additional Soliris net product sales in the remainder of 2014.
For 2014, net product revenue is now expected to be in the range of $2.15 billion - $2.17 billion, compared with the prior projected $2.0 billion - $2.02 billion range. Full-year earnings per share is now forecast between $4.37 and $4.47, versus its earlier range of between $3.70 and $3.80.
The firm said it would record increased revenue in 2014 related to a deal that brings to conclusion discussions with the French government and which positively impacts prospective reimbursement of Soliris. Also, the agreement provides reimbursement for shipments of Soliris made prior to January 1, 2014.
For the first quarter of 2014, the company would generate around $88 million of additional net product sales related to reimbursement for product sales in prior years.
Alexion is confirmed the other elements of its 2014 financial guidance.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Alexion Pharmaceuticals Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |